#USA #New York #Rosen Law Firm #securities lawsuit #Actinium Pharmaceuticals

Actinium Pharmaceuticals Securities Fraud Lawsuit Opportunity

Investors in Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) have a promising opportunity to participate in a class action lawsuit regarding securities fraud. If you purchased securities between October 31, 2022, and August 2, 2024, you may be eligible for compensation without incurring out-of-pocket costs, thanks to the contingency fee arrangement provided by the Rosen Law Firm, an established global investor rights law firm.

Key Actions for Investors

The firm emphasizes the urgency of this opportunity, as the deadline for leading plaintiffs in the case is set for May 26, 2025. Prospective plaintiffs interested in representing their peers in this litigation can submit their interest through the Rosen Law Firm's website or contact attorney Phillip Kim directly.

The Importance of Qualified Representation

The Rosen Law Firm encourages investors to choose experienced legal counsel adept in handling securities class actions. Many firms that send notifications lack the necessary resources and reputation for effective litigation, often serving only as intermediaries. The Rosen Law Firm has a proven track record, holding the title for the largest securities class action settlement against a Chinese company at one point. Since 2013, they have consistently ranked in the top four for securities class action settlements, recovering hundreds of millions for investors.

Background of the Case

According to the allegations, during the specified class period, Actinium Pharmaceuticals misrepresented key aspects of its business and operations. The lawsuit outlines that:
1. Data from the Sierra Trial was unlikely to meet FDA guidelines for approval of Actinium's Iomab-B Biologics License Application.
2. The additional analyses presented to the FDA were expected to fall short of the necessary standards.
3. If reviewed by the FDA, the chances of approval for the Iomab-B BLA were minimal.
4. Consequently, statements made by the defendants regarding Actinium's business prospects were deemed materially misleading.

When the truth about these misrepresentations became public, the lawsuit claims that affected investors incurred financial damages. This legal action serves as a crucial avenue for aggrieved shareholders to recoup losses sustained during the aforementioned class period.

Joining the Class Action

For those impacted, joining the class action is straightforward. Interested parties can visit the Rosen Law Firm’s submission page or contact the firm by phone or email for further details about participation.

It is critical to note that no class has been certified yet and that to be represented in the lawsuit, investors must either retain counsel or choose to remain passive. However, it is essential to understand that participation as lead plaintiff does not affect the potential for recovery in the case.

For continuous updates, the Rosen Law Firm encourages following their social media channels on platforms like LinkedIn, Twitter, and Facebook.

Conclusion

Investing in the legal pursuits against securities fraud can be an overwhelming task; however, this class action presents a structured pathway for potential recovery for those affected by Actinium Pharmaceuticals' alleged misconduct. As the deadline approaches, those interested in participating are urged to act decisively to secure their chance at justice.